De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
ProPhase Labs Beheer
Beheer criteriumcontroles 1/4
De CEO ProPhase Labs' is Ted Karkus, benoemd in Jun2009, heeft een ambtstermijn van 15.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.37M, bestaande uit 20% salaris en 80% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 16.85% van de aandelen van het bedrijf, ter waarde $ 7.23M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.8 jaar en 10.4 jaar.
Belangrijke informatie
Ted Karkus
Algemeen directeur
US$3.4m
Totale compensatie
| Percentage CEO-salaris | 20.0% |
| Dienstverband CEO | 15.3yrs |
| Eigendom CEO | 16.9% |
| Management gemiddelde ambtstermijn | less than a year |
| Gemiddelde ambtstermijn bestuur | 10.4yrs |
Recente managementupdates
Recent updates
Market Cool On ProPhase Labs, Inc.'s (NASDAQ:PRPH) Revenues Pushing Shares 26% Lower
Jul 03
Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?
Mar 04ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry
Jan 09ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate
Sep 21Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt
Aug 11We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease
Apr 07ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly
Jan 24ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential
Oct 13ProPhase Labs Q2 2022 Earnings Preview
Aug 10We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt
Jul 26ProPhase Labs to license two investigational cancer compounds from Global BioLife
Jul 21ProPhase Labs: A Stellar Quarter And Another Special Dividend
May 16ProPhase Labs (NASDAQ:PRPH) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Apr 08ProPhase Labs (NASDAQ:PRPH) Is Using Debt Safely
Mar 23Rock star Growth Puts ProPhase Labs (NASDAQ:PRPH) In A Position To Use Debt
Nov 30As Employer Vaccine Mandates Fail, Prophase Labs Could Benefit
Oct 20Calculating The Fair Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)
Jul 22ProPhase Labs Is A Potential Pure Play On Worries About The Delta And Delta Plus Covid-19 Variants
Jun 28Here's Why Shareholders May Consider Paying ProPhase Labs, Inc.'s (NASDAQ:PRPH) CEO A Little More
May 14ProPhase Labs partners with Dutchess County New York to provide COVID-19 testing
May 06A Look At The Intrinsic Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)
Apr 12Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$26m |
| Mar 31 2024 | n/a | n/a | -US$24m |
| Dec 31 2023 | US$3m | US$675k | -US$17m |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$4m |
| Mar 31 2023 | n/a | n/a | US$7m |
| Dec 31 2022 | US$902k | US$675k | US$18m |
| Sep 30 2022 | n/a | n/a | US$31m |
| Jun 30 2022 | n/a | n/a | US$27m |
| Mar 31 2022 | n/a | n/a | US$18m |
| Dec 31 2021 | US$941k | US$590k | US$6m |
| Sep 30 2021 | n/a | n/a | -US$5m |
| Jun 30 2021 | n/a | n/a | -US$2m |
| Mar 31 2021 | n/a | n/a | -US$460k |
| Dec 31 2020 | US$445k | US$125k | -US$2m |
| Sep 30 2020 | n/a | n/a | -US$2m |
| Jun 30 2020 | n/a | n/a | -US$2m |
| Mar 31 2020 | n/a | n/a | -US$3m |
| Dec 31 2019 | US$249k | US$125k | -US$3m |
| Sep 30 2019 | n/a | n/a | -US$3m |
| Jun 30 2019 | n/a | n/a | -US$4m |
| Mar 31 2019 | n/a | n/a | -US$3m |
| Dec 31 2018 | US$2m | US$210k | -US$2m |
| Sep 30 2018 | n/a | n/a | -US$1m |
| Jun 30 2018 | n/a | n/a | -US$826k |
| Mar 31 2018 | n/a | n/a | -US$1m |
| Dec 31 2017 | US$2m | US$675k | -US$2m |
Compensatie versus markt: De totale vergoeding ($USD 3.37M ) Ted } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).
Compensatie versus inkomsten: De vergoeding van Ted is gestegen terwijl het bedrijf verliesgevend is.
CEO
Ted Karkus (65 yo)
15.3yrs
Tenure
US$3,367,200
Compensatie
Mr. Ted William Karkus has served as the Chief Executive Officer of ProPhase Labs, Inc. since June 2009. Mr. Karkus founded 2001 Forrester Financial LLC and served as its Managing Member. He is a Managemen...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 15.3yrs | US$3.37m | 16.85% $ 7.2m | |
| Chief Operating Officer & Head of Finance Department | less than a year | geen gegevens | geen gegevens | |
| Executive VP & Chief Information Officer | less than a year | geen gegevens | geen gegevens | |
| Senior VP and Director of Sales & Marketing - Nebula Genomics | 1.8yrs | geen gegevens | geen gegevens | |
| President of Nebula Genomics | less than a year | geen gegevens | geen gegevens | |
| Corporate Controller | less than a year | geen gegevens | geen gegevens |
0.8yrs
Gemiddelde duur
Ervaren management: Het managementteam van PRPH wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 15.3yrs | US$3.37m | 16.85% $ 7.2m | |
| Independent Director | 15.3yrs | US$223.00k | 0.54% $ 233.6k | |
| Independent Director | 5.4yrs | US$223.00k | 0% $ 0 | |
| Independent Director | less than a year | geen gegevens | geen gegevens |
10.4yrs
Gemiddelde duur
65.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van PRPH zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.4 jaar).